NFNegar Firouzabadi

Negar Firouzabadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Negar Firouzabadi has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Nahid Alimoradi

    Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

    9 shared publications
  • Ehsan Bahramali

    Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

    7 shared publications
  • Ehsan Bahramali

    Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

    7 shared publications
  • Reihaneh Fatehi

    Department of Pharmacology & Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

    5 shared publications
  • Hooman Bakhshandeh

    Department of Epidemiology and Biostatistics, Rajaee Heart Center, Tehran University of Medical Sciences, Tehran, Iran

    4 shared publications
  • Kamiar Zomorrodian

    Department of Medical Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    4 shared publications

Latest Publications

  • Sertraline Has Anticancer Effects and Enhances the Cytotoxicity of Chemotherapeutic Agents Against Pancreatic Cancer Cells

    by Maedeh Shahrabi, Asma Aliparast, Fatemeh Moosavi, Amirsajad Jafari, Negar Firouzabadi, Omidreza Firuzi

    Sertraline, a serotonin reuptake inhibitor (SSRI), has been implicated as a drug with repurposing capacities in cancer. This study aimed to evaluate the anticancer efficacy of sertraline alone and in combination with chemotherapeutic agents against pancreatic ductal adenocarcinoma (PDAC) cells. Antiproliferative effects of sertraline and chemotherapeutic agents against SUIT‐2, AsPC‐1, and MIA‐PaCa‐2 PDAC cells, either alone or in combination, were determined by MTT assay. Synergistic combinations were further evaluated by clonogenic assays, cell cycle analysis, and Hoechst 33258 apoptosis staining. Reactive oxygen species (ROS) levels were quantified using the DCFH‐DA assay. Sertraline exhibited antiproliferative activity against PDAC cells (IC 50 = 8.3–16.4 µM). When combined with gemcitabine or mitoxantrone, synergistic cytotoxicity was observed in most cell lines; however, the sertraline–gemcitabine combination demonstrated an additive effect in MIA‐PaCa‐2 cells. Mean CI values of 0.54 ± 0.06 and 0.80 ± 0.03 in SUIT‐2 cells, 0.81 ± 0.04 and 0.79 ± 0.06 in AsPC‐1 cells, and 1.06 ± 0.05 and 0.79 ± 0.05 in MIA‐PaCa‐2 cells, respectively. These combinations suppressed colony formation, altered the cell cycle, and enhanced apoptosis. Additionally, increased ROS generation was observed, particularly in the sertraline–gemcitabine combination, suggesting that oxidative stress may contribute to this interaction. Combinations with doxorubicin or cisplatin did not lead to synergism. These findings provide a rationale for further investigation of sertraline‐based combination strategies in pancreatic cancer.

  • Open Access

    Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms

    by Kiana Yousefipour, Seyed Soheil Razavi Rohani, Sayed Mohammad Mahdi Hosseini, Kianaz Kafilzadeh, Nafiseh Sadat Alavi, Negar Firouzabadi

    Gastrointestinal (GI) cancers are among the most common cancers of the decade, many of which have a poor prognosis. Due to the high prevalence of toxicity and adverse drug reactions (ADRs) of chemotherapeutic agents and low patient compliance, there is always a need for drugs that can be used as adjuvants to existing cancer treatments with low ADRs which can boost the efficacy of chemotherapeutics and reduce the associated toxicities. Repurposing or repositioning a drug with known pharmacological properties is of great value in this context. Drug repurposing has been applied in many illnesses in the recent decade. Melatonin is an endogenous hormone with multiple anticancer properties. It demonstrates antitumor effects by modifying several critical signaling pathways, inhibiting proliferation and metastasis, inducing apoptosis and autophagy, and also reducing oxidative stress. It also reduces toxicity of chemotherapeutics. Due to specific characteristics of melatonin and its limited toxicity, melatonin can be considered as a potential for repositioning in various cancers. Hence, melatonin can be included as an off-label adjuvant chemotherapy to improve the prognosis and overall quality of life of patients suffering from GI cancers. Herein, the action of melatonin on various GI cancers, with the emphasis on its effect on major oncogenic signaling pathways (e.g., Wnt/β-catenin signaling pathway, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), and nuclear factor kappa B (NF-κB)) are discussed. Additionally, mechanisms by which melatonin halts the process of mitosis, induces apoptosis, and makes tumors more vulnerable to chemotherapy are discussed.


  • Evaluation of the circulating levels of IL-33 in patients with osteoarthritis: role of rs1929992 variants

    by Nahid Alimoradi, Fatemeh Jahankhah, Habibollah Jokardarzi, Mohammad Tahami, Negar Firouzabadi

  • Binding interaction of food preservatives with glycosylated DNA: In vitro assessment and computational studies

    by Leila Emami, Somayeh Hoshyar, Samaneh Bina, Fateme Zare, Pegah Mardaneh, Marziyeh Haghshenas, Alireza Poustforoosh, Negar Firouzabadi, Marzieh Rashedinia


  • Open Access

    Metformin Exhibits Anti‐Inflammatory Effects by Regulating microRNA‐451/CXCL16 and B Cell Leukemia/Lymphoma 2 in Patients With Osteoarthritis

    by Nahid Alimoradi, Amin Ramezani, Mohammad Tahami, Negar Firouzabadi

    Objective: Osteoarthritis (OA) is the most common cause of chronic disability in joints among older individuals. The primary goal of OA treatment is pain relief to improve the quality of life. Inflammation and aging are involved in the pathogenesis of pain in OA. In this study, we evaluated the ability of metformin to regulate microRNAs, such as miR‐451 and miR‐15b, and their target proteins, CXCL16 and B cell leukemia/lymphoma 2 (BCL‐2), involved in inflammation and apoptosis.Methods: In this double‐blind placebo‐controlled clinical trial, patients were randomly divided into two groups: one receiving metformin and the other receiving a placebo for four months (starting at 0.5 g/day for the first week, increasing to 1 g/day for the second week, and increasing to 1.5 g/day for the remaining period). In addition to evaluating the clinical response using the Knee Injury and Osteoarthritis Outcome Score questionnaire, miR‐451 and miR‐15b expression levels were detected using real‐time polymerase chain reaction. The serum levels of CXCL16 and BCL‐2 were evaluated using enzyme‐linked immunosorbent assay kits before (time zero) and after treatment (month four).Results: Metformin increased miR‐451 expression levels simultaneously with pain reduction, whereas miR‐15b expression did not change significantly after four months of treatment. Also, metformin decreased the serum levels of BCL‐2 and CXCL16 in patients with OA.Conclusion: The effects of metformin in reducing pain can be attributed to many factors, including its anti‐inflammatory and antiaging effects. Our findings suggest that metformin may reduce pain and inflammation in patients with OA through the regulation of miR‐451/CXCL16 and BCL‐2.


  • Open Access

    Modulation of ACE2/Ang1-7/Mas and ACE/AngII/AT1 axes affects anticancer properties of sertraline in MCF-7 breast cancer cells

    by Reihaneh Fatehi, Mohammad Nouraei, Morteza Panahiyan, Marzieh Rashedinia, Negar Firouzabadi


  • Top Cited Papers
    Open Access

    The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies

    by Bahareh Hassani, Zeinab Attar, Negar Firouzabadi

    The renin-angiotensin-aldosterone system (RAAS), is an old system with new fundamental roles in cancer biology which influences cell growth, migration, death, and metastasis. RAAS signaling enhances cell proliferation in malignancy directly and indirectly by affecting tumor cells and modulating angiogenesis. Cancer development may be influenced by the balance between the ACE/Ang II/AT1R and the ACE2/Ang 1–7/Mas receptor pathways. The interactions between Ang II/AT1R and Ang I/AT2R as well as Ang1-7/Mas and alamandine/MrgD receptors in the RAAS pathway can significantly impact the development of cancer. Ang I/AT2R, Ang1-7/Mas, and alamandine/MrgD interactions can have anticancer effects while Ang II/AT1R interactions can be involved in the development of cancer. Evidence suggests that inhibitors of the RAAS, which are conventionally used to treat cardiovascular diseases, may be beneficial in cancer therapies.Herein, we aim to provide a thorough description of the elements of RAAS and their molecular play in cancer. Alongside this, the role of RAAS components in sex-dependent cancers as well as GI cancers will be discussed with the hope of enlightening new venues for adjuvant cancer treatment.Graphical abstract


  • Open Access

    Polymorphism of glucocorticoid receptor gene (rs41423247) in functional seizures (psychogenic nonepileptic seizures/attacks)

    by Negar Firouzabadi, Ali A. Asadi‐Pooya, Nahid Alimoradi, Leila Simani, Marjan Asadollahi

    Objective: We investigated the association between the glucocorticoid receptor (GR) gene, also known as the nuclear receptor subfamily 3, group C, member 1 (NR3C1), rs41423247 polymorphism, and functional seizures (psychogenic nonepileptic seizures/attacks) in a case–control study. We hypothesized that the tested polymorphism has significant associations with functional seizures (psychogenic nonepileptic seizures/attacks) independent from comorbid depression.Methods: Seventy patients with functional seizures (psychogenic nonepileptic seizures/attacks), 70 with major depressive disorder (MDD), and 70 healthy controls (HCs) were studied. Their DNAs were analyzed for NR3C1 rs41423247 polymorphism.Results: Genotype and allele frequencies of rs41423247 were different between the three groups. G allele carriers were more frequent in patients with functional seizures (psychogenic nonepileptic seizures/attacks) and those with MDD compared to HCs (p = 0.0001). However no significant difference was observed with respect to allele distributions between functional seizures (psychogenic nonepileptic seizures/attacks) and MDD groups (p = 0.391). CC genotype was less often associated with functional seizures (psychogenic nonepileptic seizures/attacks) versus HC: Codominant model; p = 0.001, OR = 0.11, 95% CI = 0.05–0.24, and −2loglilkelihood = 231.7. In comparison between functional seizures (psychogenic nonepileptic seizures/attacks) group and other (MDD + HC) groups, we observed a significant association between CG genotype and functional seizures (psychogenic nonepileptic seizures/attacks) (Codominant model; p = 0.001, OR = 5.63, 95% CI = 2.60–12.40 and −2loglikelihood = 245.99).Significance: Patients with functional seizures (psychogenic nonepileptic seizures/attacks) and those with MDD were significantly more often G allele carriers in rs41423247 compared with HCs. We observed a significant association between CG genotype and functional seizures (psychogenic nonepileptic seizures/attacks). However, we could not exclude the possibility of confounding effects of depression. Future genetic studies of patients with functional seizures (psychogenic nonepileptic seizures/attacks) should include a comparison group with depression in addition to a comparison group of HCs.


  • Open Access

    Potential role of FKBP5 single‐nucleotide polymorphisms in functional seizures

    by Ali A. Asadi‐Pooya, Leila Simani, Marjan Asadollahi, Fatemeh Sadat Rashidi, Ehsan Ahmadipour, Afagh Alavi, Mehrdad Roozbeh, Nayyereh Akbari, Negar Firouzabadi

    Objective: We investigated the associations between FKBP5 single‐nucleotide polymorphisms (SNPs) and functional seizures (FS).Methods: Seventy patients with FS, 140 with major depressive disorder (MDD), and 140 healthy controls were studied. Their DNAs were analyzed for the rs1360780 in the 3′ region and rs9470080 in the 5′ region of the FKBP5. Childhood trauma questionnaire and hospital anxiety and depression scale were used.Results: Patients with FS and those with MDD had less GG and more AA genotypes in both rs9470080 and rs1360780 SNPs compared with those in healthy controls. Similar results were observed for allelic frequencies. There were no significant differences between FS and MDD groups in terms of genotype and allelic frequencies for both SNPs. The results of multinomial logistic regression analysis showed that FKBP5 polymorphisms were not associated with the diagnosis.Significance: Patients with FS and those with MDD had significantly different genotypes in both rs9470080 and rs1360780 SNPs compared with those in healthy controls. However, it seems that FKBP5 polymorphisms were not associated with FS in the absence of depression. Further genetic investigations of patients with FS may increase our understanding of the neurobiological underpinnings of this condition, but such studies should be large enough and very well designed; they should include a comparison group with depression in addition to a healthy control group.